Idenix Pharmaceuticals Edges Higher – Sees Slow Crawl Higher Despite Morning Downgrade

Idenix Pharmaceuticals (IDIX) is posting modest gains in today’s regular session, slowly crawling higher after sitting just above flat earlier in the day. The stock has struggled Friday in the wake of a UBS downgrade to Neutral from Buy. Further gains will be fighting against the downgrade as well as the stock’s current levels, holding just below its 52-week high of $24.21.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France.


Andy Weld, CFA, is an editor and equity analyst for The Downtown Leader. If you have a great story idea for Andy Weld, you can write at [ ].